- Poster presentation
- Open Access
Diagnostic and prognostic performance of PATHFAST Presepsin in patients with SIRS and early sepsis
Critical Care volume 19, Article number: P63 (2015)
Presepsin (sCD14-ST) serves as a mediator of the response to infectious agents. First evidence suggested that presepsin may be utilized as a sepsis marker.
Presepsin was determined at presentation (T0), after 8, 24 and 72 hours in 123 individuals admitted with signs of SIRS and/ or infection. Primary endpoint was death within 30 days. Presepsin was determined using the POC assay PATHFAST Presepsin (Mitsubishi Chemical, Japan).
Mean presepsin concentrations of the patient group at presentation and of the control group were 1,945 and 130 pg/ml, respectively (P < 0.0001). Baseline presepsin differed highly significant between patients with SIRS, sepsis, severe sepsis and septic shock. Twenty-four patients died during 30 days. The 30-day mortality was 19.5% in total, ranging from 10 to 32% between the first and the fourth quartile of presepsin concentration. Nonsurvivors showed high presepsin values with increasing tendency during the course of the disease while in surviving patients this tendency was decreasing. See Table 1.
Presepsin demonstrated a strong relationship with disease severity and outcome. Presepsin provided reliable discrimination between SIRS and sepsis as well as prognosis and early prediction of 30day mortality already at admission. Presepsin showed close association with the course of the disease.
About this article
Cite this article
Spanuth, E., Carpio, R. & Thomae, R. Diagnostic and prognostic performance of PATHFAST Presepsin in patients with SIRS and early sepsis. Crit Care 19, P63 (2015). https://doi.org/10.1186/cc14143
- Public Health
- Patient Group
- Disease Severity
- Primary Endpoint
- Septic Shock